Výsledky vyhledávání - "Mats Ekelund"

Akademický článek

All-cause pneumonia hospitalizations in children

Autor: Anders Berglund, Mats Ekelund, Mark A Fletcher, Lars Nyman

Publikováno v: PLoS ONE, Vol 9, Iss 11, p e112211 (2014)

In late 2007, some Swedish County Councils started 7-valent pneumococcal conjugate vaccine (PCV7) implementation for children, and PCV7 was included in the national immunization program in 2009. By 2010, both PCV10 and PCV13 were licensed, and the se

Externí odkaz: https://doaj.org/article/ceb8f8a184e049218fe1a654d0c45526

Zobrazit plný text záznamu

Modeling the cost-effectiveness of prolonged-release fampridine for the treatment of walking impairment in patients with multiple sclerosis in Sweden

Autor: Thomas Lundqvist, Mattia Gianinazzi, Jan Lycke, Nigel Armstrong, Mats Ekelund, Steve Ryder, Carlos Acosta, Thibaut Dort

Publikováno v: Journal of medical economics. 24(1)

Aims To evaluate the cost-effectiveness of adding prolonged-release (PR)-fampridine to best supportive care (BSC) versus BSC alone for the improvement of walking ability in patients with MS. Methods A cost-utility analysis based on a Markov model was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1a908717c9bf2ed451c8981c3336192
https://pubmed.ncbi.nlm.nih.gov/33966549

Zobrazit plný text záznamu

Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study

Autor: Ulrich Baumann, Paresh N. Soni, Henrik Arnell, Per-Göran Gillberg, Kristina Torfgard, Björn Fischler, Marianne Hørby Jørgensen, Ekkehard Sturm, Emmanuel Gonzales, Mats Ekelund, Florence Lacaille, Richard J. Thompson, Jan P. Mattsson, Erik Lindström

Publikováno v: Clinics and Research in Hepatology and Gastroenterology. 45:101751

Purpose Ileal bile acid transporter inhibition is a novel therapeutic concept for cholestatic pruritus and cholestatic liver disease progression. Odevixibat, a potent, selective, reversible ileal bile acid transporter inhibitor, decreases enteric bil

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33aab09eeb36a8e2b534f59acb8adeb9
https://doi.org/10.1016/j.clinre.2021.101751

Zobrazit plný text záznamu

Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden

Autor: Adrian D. Vickers, Andrew Lloyd, Santiago Zuluaga-Sanchez, Robin Thompson, Annabelle Forsmark, Christopher Knight, Megan Teynor, Thomas Lundqvist, Mats Ekelund

Publikováno v: PharmacoEconomics. 37(6)

Spinal muscular atrophy is a rare neuromuscular disorder with a spectrum of severity related to age at onset and the number of SMN2 gene copies. Infantile-onset (≤ 6 months of age) is the most severe spinal muscular atrophy and is the leading monog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cce8365b361401d51647d81540da8de3
https://pubmed.ncbi.nlm.nih.gov/30714083

Zobrazit plný text záznamu

An open prospective study evaluating efficacy and safety of a new medical device for rectal application of activated carbon in the treatment of chronic, uncomplicated perianal fistulas

Autor: C. Johansson, Antoni Zawadzki, Ole Haagen Nielsen, M. Bohe, Louis Banka Johnson, Mats Ekelund

Publikováno v: Zawadzki, A, Johnson, L B, Bohe, M, Johansson, C, Ekelund, M & Nielsen, O H 2017, ' An open prospective study evaluating efficacy and safety of a new medical device for rectal application of activated carbon in the treatment of chronic, uncomplicated perianal fistulas ', International Journal of Colorectal Disease, vol. 32, no. 4, pp. 509-512 . https://doi.org/10.1007/s00384-016-2726-z
International Journal of Colorectal Disease

PURPOSE: It has been proposed that biological/chemical substances in the intestine might play a role in the occurrence and deterioration of perianal fistulas. Elimination of such unidentified factors from the lower gastrointestinal tract might offer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15673199a32d4a3610a4964367741c42
https://doi.org/10.1007/s00384-016-2726-z

Zobrazit plný text záznamu

Direct and indirect costs for anal fistula in Sweden

Autor: Mats Ekelund, Frida Hjalte, Adam Lundqvist, Ida Ahlberg

Publikováno v: International Journal of Surgery. 35:129-133

Introduction Anal fistula is an abnormal tract with an external and internal opening that cause leakage, discomfort, and occasionally pain. Surgery is standard treatment, but recurrence and anal incontinence is common. The objective of the study was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54069d5864b7b264d7b3c41d37583c1d
https://doi.org/10.1016/j.ijsu.2016.09.082

Zobrazit plný text záznamu

A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model

Autor: Mats Ekelund, Ron Akehurst, Nicholas Brereton, Becky Pennington

Publikováno v: Journal of Medical Economics. 17:677-684

Celecoxib for the treatment of pain resulting from osteoarthritis (OA) was reviewed by the Tandvårds- och läkemedelsförmånsverket-Dental and Pharmaceutical Benefits Board (TLV) in Sweden in late 2010. This study aimed to evaluate the incremental

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::514869d91a9ada51ed40de1e75e55512
https://doi.org/10.3111/13696998.2014.933111

Zobrazit plný text záznamu

A Higher Score on the Dermatology Life Quality Index, Being on Systemic Treatment and Having a Diagnosis of Psoriatic Arthritis is Associated with Increased Costs in Patients with Plaque Psoriasis

Autor: Berndt Stenberg, Lotus Mallbris, Susanne Qvitzau, Mats Ekelund

Publikováno v: Acta Dermato Venereologica. 93:684-688

The aim of this study was to examine the relationship between measures of disease severity and costs from a socie-tal perspective in patients with plaque psoriasis. Dermatologists in Sweden recruited 443 consecutive patients who had had no biological

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4ee219829bb4d1ba619d60581415a6c
https://doi.org/10.2340/00015555-1591

Zobrazit plný text záznamu

Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries

Autor: Susanne Qvitzau, Andrew J. K. Östör, Alan Reynolds, Rose-Marie Lindkvist, Mats Ekelund, Per Larsson, Robert J. Moots, Pentti Järvinen, Anne G. R. Loft, Danuta Kielar

Publikováno v: Moots, R J, Ostor, A J K, Loft, A G R, Järvinen, P, Larsson, P, Ekelund, M, Reynolds, A, Kielar, D, Lindkvist, R-M & Qvitzau, S 2012, ' Reduction of direct and indirect costs in patients with AS receiving etanercept : results from an open-label 36-week extension of the ASCEND study in four European countries ', Rheumatology, vol. 51, no. 2, pp. 393-6 . https://doi.org/10.1093/rheumatology/ker404

OBJECTIVE: To characterize the impact of etanercept (ETN) in AS on cost, work productivity and quality of life (QoL).METHODS: A Phase 4, open-label, multi-centre (UK, Scandinavia) extension study in AS. Eligible subjects (n = 84) were treated for 36-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1bf42659488942e087c8e5568d93c17
https://doi.org/10.1093/rheumatology/ker404

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání